AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten micro-challenge
Description: From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inadvertent gluten challenge
Description: From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inadvertent gluten challenge
Description: From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate gluten challenge
Description: From week 36 to week 42, all participants will be on gluten 2g/day.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate gluten challenge
Description: From week 36 to week 42, all participants will be on gluten 2g/day.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal diet
Description: From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Necator americanus-hookworm larvae L3-10
Description: A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tabasco® Sauce
Description: Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Necator americanus-hookworm larvae L3-20
Description: A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: From week 0 to week 12, all participants will be on a gluten free diet.
Study NCT02754609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten free diet
Description: From week 0 to week 12, all participants will be on a gluten free diet.
Study NCT03076359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Healer Support Program
Description: Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients.
Study NCT03076359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
Study NCT03076359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
Study NCT00147979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridging by PTFE with bounded heparin
Description: Bridging by PTFE with bounded heparin
Study NCT00147979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bridging by PTFE without bounded heparin
Description: Bridging by PTFE without bounded heparin
Study NCT02268396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
Description: GFF MDI administered as 2 inhalations BID
Study NCT01109303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TightRope System- Arthrex® / Dynamic Implant
Description: Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
Study NCT01109303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screw fixation - Synthes® / Static Implant
Description: Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
Study NCT02590133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Endostatin Injection (Endostar)
Description: 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Study NCT02590133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-Fu)
Description: 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Study NCT01455090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Study NCT00754507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam HCl tablets, and atorvastatin tablets
Description: colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
Study NCT00754507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colesevelam HCl placebo tablets and atorvastatin tablets
Description: colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
Study NCT02590133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-Fu)
Description: 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Study NCT00675285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet 5 mg once/day for 4 weeks
Study NCT02590133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
Study NCT02590133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
Study NCT01808443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: up to a maximum of four treatments every 21-28 days
Study NCT01808443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser
Description: up to a maximum of four treatments every 21-28 days
Study NCT03138083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-1
Description: OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
Study NCT02236585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled epidural analgesia
Description: Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
Study NCT02236585 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous epidural analgesia
Description: Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
Study NCT01311596 — intervention group
Intervention type: OTHER
Intervention: Icons
Description: Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
Study NCT01947738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBY-891
Description: Cathepsin S inhibitor
Study NCT01947738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04122053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group with genotype information
Description: Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.
Study NCT04122053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group without genotype information
Description: Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
Study NCT03739385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
Study NCT03739385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
Study NCT02372331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS perioperative management
Description: * Preop Counseling~* Preop biliary drainage (X) when Serum Total bilirubin \< 14.62mg/dl and cholangitis (-)~* Preop enteral nutrition~* Oral bowel preparation (mechanical bowel preparation ) (X)~* Preop fasting \< 6 hours~* Prevention of postoperative nausea and vomiting (PONV) (O)~* Nasogastric intubation (X)~* Near-zero fluid balance~* Somatostatin analogues (X)~* Postop routine artificial nutrition (X), soft diet at POD #2~* Audit~* Other items are same as conventional
Study NCT02187211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Study NCT02187211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Minocycline)
Study NCT03708380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Over a 60-day period, participants will receive healthy lunches that provide a hand-delivered healthy alterative to their current diets.
Study NCT04612114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Belun Ring
Description: Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.
Study NCT01540435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
Study NCT01421043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triazolam liquid oral drops
Description: 0.25 mg single dose oral drops
Study NCT01421043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triazolam tablets
Description: 0.25 mg single oral dose
Study NCT01547104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
Study NCT01547104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
Study NCT01333943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Group: Experimental
Description: The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
Study NCT01333943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
Study NCT06163716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (MD-Int) group
Description: The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
Study NCT03701425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet and exercise plan
Description: Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%
Study NCT03701425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and exercise plan
Description: Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%
Study NCT01561690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-502, CRTh2 antagonist; oral
Description: multiple dose, single schedule
Study NCT01561690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study NCT03483077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730460
Description: tablets
Study NCT03483077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study NCT04292847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referrals Recommendations
Description: All participants will complete the geriatric assessment and receive Referral recommendations based on the assessment.
Study NCT00505245 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Complete interview
Study NCT00505245 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life assessment
Study NCT00505245 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT00563992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
Study NCT00563992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
Study NCT03904628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 capsules oral administration, BIW in every 28d
Description: TG02 capsules150mg oral administration, BIW in every 28d
Study NCT03904628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 capsules oral administration, BIW in every 28d
Description: TG02 capsules 200mg oral administration, BIW in every 28d
Study NCT03904628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 capsules oral administration, BIW in every 28d
Description: TG02 capsules 250mg oral administration, BIW in every 28d
Study NCT01599416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: U-relax
Description: Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
Study NCT01599416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: U-relax
Description: Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
Study NCT00773071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT/CT guided LM/SL
Description: Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
Study NCT02318225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study NCT02318225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study NCT00105885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telephone care
Description: Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
Study NCT00787943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 10.0% cream - Formulation 1
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study NCT00787943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 10.0% cream - Formulation 2
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study NCT04012320 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention, observational study
Study NCT01637493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
Study NCT03941938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate reinforcement
Description: Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line
Study NCT03941938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No reinforcement
Description: Nothing applied on the anastomosis line
Study NCT02037061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
Study NCT02037061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT02440906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Directed Wellness Account
Description: The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
Study NCT02440906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Navigator
Description: The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.